Publications

BibTex format

@article{Nazarzadeh:2022:10.1016/S2213-8587(22)00172-3,
author = {Nazarzadeh, M and Bidel, Z and Canoy, D and Copland, E and Bennett, DA and Dehghan, A and Davey, Smith G and Holman, RR and Woodward, M and Gupta, A and Adler, AI and Wamil, M and Sattar, N and Cushman, WC and McManus, RJ and Teo, K and Davis, BR and Chalmers, J and Pepine, CJ and Rahimi, K and Blood, Pressure Lowering Treatment Trialists' Collaboration},
doi = {10.1016/S2213-8587(22)00172-3},
journal = {The Lancet Diabetes and Endocrinology},
pages = {645--654},
title = {Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis},
url = {http://dx.doi.org/10.1016/S2213-8587(22)00172-3},
volume = {10},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Controversy exists as to whether the threshold for blood pressure-lowering treatment should differ between people with and without type 2 diabetes. We aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiovascular events by type 2 diabetes status, as well as by baseline levels of systolic blood pressure. METHODS: We conducted a one-stage individual participant-level data meta-analysis of major randomised controlled trials using the Blood Pressure Lowering Treatment Trialists' Collaboration dataset. Trials with information on type 2 diabetes status at baseline were eligible if they compared blood pressure-lowering medications versus placebo or other classes of blood pressure-lowering medications, or an intensive versus a standard blood pressure-lowering strategy, and reported at least 1000 persons-years of follow-up in each group. Trials exclusively on participants with heart failure or with short-term therapies and acute myocardial infarction or other acute settings were excluded. We expressed treatment effect per 5 mm Hg reduction in systolic blood pressure on the risk of developing a major cardiovascular event as the primary outcome, defined as the first occurrence of fatal or non-fatal stroke or cerebrovascular disease, fatal or non-fatal ischaemic heart disease, or heart failure causing death or requiring hospitalisation. Cox proportional hazard models, stratified by trial, were used to estimate hazard ratios (HRs) separately by type 2 diabetes status at baseline, with further stratification by baseline categories of systolic blood pressure (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg). To estimate absolute risk reductions, we used a Poisson regression model over the follow-up duration. The effect of each of the five major blood pressure-lowering drug classes, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β blockers, calcium channel blockers, and th
AU  - Nazarzadeh,M
AU  - Bidel,Z
AU  - Canoy,D
AU  - Copland,E
AU  - Bennett,DA
AU  - Dehghan,A
AU  - Davey,Smith G
AU  - Holman,RR
AU  - Woodward,M
AU  - Gupta,A
AU  - Adler,AI
AU  - Wamil,M
AU  - Sattar,N
AU  - Cushman,WC
AU  - McManus,RJ
AU  - Teo,K
AU  - Davis,BR
AU  - Chalmers,J
AU  - Pepine,CJ
AU  - Rahimi,K
AU  - Blood,Pressure Lowering Treatment Trialists' Collaboration
DO  - 10.1016/S2213-8587(22)00172-3
EP  - 654
PY  - 2022///
SN  - 2213-8595
SP  - 645
TI  - Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
T2  - The Lancet Diabetes and Endocrinology
UR  - http://dx.doi.org/10.1016/S2213-8587(22)00172-3
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35878651
UR  - https://www.sciencedirect.com/science/article/pii/S2213858722001723?via%3Dihub
UR  - http://hdl.handle.net/10044/1/99116
VL  - 10
ER  -

Download

ProfessorPeterSever

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)